^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | ImmuFact (eftilagimod alpha) (APC activator, MHC II agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma
Excerpt:
...Metastatic oestrogen receptor positive and/or progesterone receptor positive breast adenocarcinoma, histologically proven by biopsy of the primary tumour and/or metastasis...
Trial ID:
Source:
Title:
171P - Biomarker and multivariate analyses results from AIPAC: A phase IIb study comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- metastatic breast cancer
Published date:
05/03/2022
Excerpt:
This double-blinded, 1:1 randomized phase IIb trial enrolled pts with HR+ HER2- MBC….In the multivariate predictive model 4 groups (high Neutrophil/Lymphocyte Ratio [NLR]; no prior taxanes; low monocytes and <5 yrs since diagnosis) were significant for OS (Table). On treatment mean fold-changes of monocytes (5.81 vs. 2.29; p=0.025), PBMCs (2.00 vs. 1.41; p=0.041), T cells (2.28 vs. 1.48; p=0.086), & CXCL10 (2.78 vs. 1.56; p=0.06) were significantly higher (EF vs PL) and linked to higher OS. Post baseline CD4 (median 896/μl vs. 736 μl; p=0.038) & CD8 (median 377/μl vs. 223 μl; p=0.005) T cell count increased significantly in pts with higher OS....EF + PA elicits significant effects on different immune cells which is significantly associated with higher OS.
Secondary therapy:
paclitaxel
Trial ID:
Title:
Immutep Reports Statistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast Cance
Published date:
12/10/2020
Excerpt:
Immutep Limited...report encouraging first Overall Survival (OS) follow up data from its ongoing Phase IIb AIPAC study evaluating Immutep’s lead product candidate eftilagimod alpha in combination with paclitaxel chemotherapy (“efti group”)...in patients with HER2-negative/HR positive metastatic breast cancer...Promising and improving overall trend in OS in total population (based on approx. 60% of events): median survival benefit of +2.7 monthsfrom efti plus chemotherapy, compared to chemotherapy plus placebo...
Secondary therapy:
paclitaxel
Trial ID:
